These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 33565080)

  • 1. Outcome of dogs with intermediate grade low mitotic index high Ki67 mast cell tumours treated with surgery and single agent lomustine.
    Néčová S; Mason SL; North SM
    Aust Vet J; 2021 May; 99(5):146-151. PubMed ID: 33565080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant CCNU (lomustine) and prednisone chemotherapy for dogs with incompletely excised grade 2 mast cell tumors.
    Hosoya K; Kisseberth WC; Alvarez FJ; Lara-Garcia A; Beamer G; Stromberg PC; Couto CG
    J Am Anim Hosp Assoc; 2009; 45(1):14-8. PubMed ID: 19122059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of minichromosome maintenance protein 7, Ki67 and mitotic index in the prognosis of intermediate Patnaik grade cutaneous mast cell tumours in dogs.
    Berlato D; Murphy S; Laberke S; Rasotto R
    Vet Comp Oncol; 2018 Dec; 16(4):535-543. PubMed ID: 29989314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aggressive local therapy combined with systemic chemotherapy provides long-term control in grade II stage 2 canine mast cell tumour: 21 cases (1999-2012).
    Lejeune A; Skorupski K; Frazier S; Vanhaezebrouck I; Rebhun RB; Reilly CM; Rodriguez CO
    Vet Comp Oncol; 2015 Sep; 13(3):267-80. PubMed ID: 23721492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison between Ki-67 index and mitotic index for predicting outcome in canine mast cell tumours.
    van Lelyveld S; Warland J; Miller R; Maw H; Foale R; Goodfellow M; Dobson J
    J Small Anim Pract; 2015 May; 56(5):312-9. PubMed ID: 25728289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recurrence rates and clinical outcome for dogs with grade II mast cell tumours with a low AgNOR count and Ki67 index treated with surgery alone.
    Smith J; Kiupel M; Farrelly J; Cohen R; Olmsted G; Kirpensteijn J; Brocks B; Post G
    Vet Comp Oncol; 2017 Mar; 15(1):36-45. PubMed ID: 25643820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of canine mast cell tumors with CCNU (lomustine).
    Rassnick KM; Moore AS; Williams LE; London CA; Kintzer PP; Engler SJ; Cotter SM
    J Vet Intern Med; 1999; 13(6):601-5. PubMed ID: 10587263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pulse-Administered Toceranib Phosphate Plus Lomustine for Treatment of Unresectable Mast Cell Tumors in Dogs.
    Burton JH; Venable RO; Vail DM; Williams LE; Clifford CA; Axiak-Bechtel SM; Avery AC; Thamm DH
    J Vet Intern Med; 2015; 29(4):1098-104. PubMed ID: 26119008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Ki67 index with prognosis for intermediate-grade canine cutaneous mast cell tumours.
    Maglennon GA; Murphy S; Adams V; Miller J; Smith K; Blunden A; Scase TJ
    Vet Comp Oncol; 2008 Dec; 6(4):268-74. PubMed ID: 19178685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lomustine (CCNU) and prednisone chemotherapy for high-grade completely excised canine mast cell tumors.
    Hay JK; Larson VS
    Can Vet J; 2019 Dec; 60(12):1326-1330. PubMed ID: 31814640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of mitotic index and Ki67 index in the prognostication of canine cutaneous mast cell tumours.
    Berlato D; Murphy S; Monti P; Stewart J; Newton JR; Flindall A; Maglennon GA
    Vet Comp Oncol; 2015 Jun; 13(2):143-50. PubMed ID: 23489679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospective outcome evaluation for dogs with surgically excised, solitary Kiupel high-grade, cutaneous mast cell tumours.
    Moore AS; Frimberger AE; Taylor D; Sullivan N
    Vet Comp Oncol; 2020 Sep; 18(3):402-408. PubMed ID: 31916687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination toceranib and lomustine shows frequent high grade toxicities when used for treatment of non-resectable or recurrent mast cell tumours in dogs: A European multicentre study.
    Bavcar S; de Vos J; Kessler M; de Fornel P; Buracco P; Murphy S; Hirschberger J; Argyle DJ
    Vet J; 2017 Jun; 224():1-6. PubMed ID: 28697868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant medical therapy provides no therapeutic benefit in the treatment of dogs with low-grade mast cell tumours and early nodal metastasis undergoing surgery.
    Marconato L; Stefanello D; Kiupel M; Finotello R; Polton G; Massari F; Ferrari R; Agnoli C; Capitani O; Giudice C; Aresu L; Vasconi ME; Rigillo A; Sabattini S
    Vet Comp Oncol; 2020 Sep; 18(3):409-415. PubMed ID: 31930651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A retrospective review of treatment and response of high-risk mast cell tumours in dogs.
    Miller RL; Van Lelyveld S; Warland J; Dobson JM; Foale RD
    Vet Comp Oncol; 2016 Dec; 14(4):361-370. PubMed ID: 25223579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study to evaluate the toxicity and efficacy of alternating CCNU and high-dose vinblastine and prednisone (CVP) for treatment of dogs with high-grade, metastatic or nonresectable mast cell tumours.
    Rassnick KM; Bailey DB; Russell DS; Flory AB; Kiselow MA; Intile JL; Malone EK; Balkman CE; Barnard SM
    Vet Comp Oncol; 2010 Jun; 8(2):138-52. PubMed ID: 20579327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination CCNU and vinblastine chemotherapy for canine mast cell tumours: 57 cases.
    Cooper M; Tsai X; Bennett P
    Vet Comp Oncol; 2009 Sep; 7(3):196-206. PubMed ID: 19691648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological behaviour of canine mandibular osteosarcoma. A retrospective study of 50 cases (1999-2007).
    Coyle VJ; Rassnick KM; Borst LB; Rodriguez CO; Northrup NC; Fan TM; Garrett LD
    Vet Comp Oncol; 2015 Jun; 13(2):89-97. PubMed ID: 23410097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of prognostic factors associated with outcome in dogs with multiple cutaneous mast cell tumors treated with surgery with and without adjuvant treatment: 54 cases (1998-2004).
    Mullins MN; Dernell WS; Withrow SJ; Ehrhart EJ; Thamm DH; Lana SE
    J Am Vet Med Assoc; 2006 Jan; 228(1):91-5. PubMed ID: 16426175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison between symptomatic treatment and lomustine supplementation in 71 dogs with intracranial, space-occupying lesions.
    Van Meervenne S; Verhoeven PS; de Vos J; Gielen IM; Polis I; Van Ham LM
    Vet Comp Oncol; 2014 Mar; 12(1):67-77. PubMed ID: 22738696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.